Pacific Biosciences of California (PACB) Expected to Post Quarterly Earnings on Tuesday

Posted by Stanley Muller on Oct 27th, 2026

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) is projected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Pacific Biosciences of California to announce earnings of ($0.1260) per share and revenue of $43.82 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Wednesday, November 4, 2026 at 4:30 PM ET.

Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) last issued its earnings results on Monday, August 3rd. The biotechnology company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The firm had revenue of $39.01 million during the quarter, compared to the consensus estimate of $42.90 million. Pacific Biosciences of California had a negative net margin of 82.49% and a negative return on equity of 5,752.12%. On average, analysts expect Pacific Biosciences of California to post ($0.52) EPS for the current fiscal year and ($0.48) EPS for the next fiscal year.

Pacific Biosciences of California Stock Performance

PACB opened at $2.25 on Tuesday. The firm’s fifty day moving average is $1.71 and its two-hundred day moving average is $1.60. The firm has a market cap of $699.37 million, a PE ratio of -5.23 and a beta of 2.19. Pacific Biosciences of California has a twelve month low of $1.07 and a twelve month high of $3.43.

Insiders Place Their Bets

In related news, insider James Gibson, II sold 661,815 shares of the business’s stock in a transaction on Tuesday, October 6th. The shares were sold at an average price of $3.11, for a total value of $2,058,244.65. Following the sale, the insider directly owned 1,083,848 shares of the company’s stock, valued at approximately $3,370,767.28. The trade was a 37.91% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Mark Van Oene sold 26,911 shares of the company’s stock in a transaction on Monday, August 17th. The stock was sold at an average price of $1.13, for a total transaction of $30,409.43. Following the completion of the transaction, the insider directly owned 2,705,853 shares of the company’s stock, valued at approximately $3,057,613.89. The trade was a 0.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 3.70% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts recently commented on the company. UBS Group initiated coverage on Pacific Biosciences of California in a research note on Wednesday, September 9th. They set a “neutral” rating and a $1.35 price objective on the stock. Weiss Ratings raised Pacific Biosciences of California from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, October 13th. Finally, Wall Street Zen cut Pacific Biosciences of California from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. One analyst has rated the stock with a Buy rating, three have assigned a Hold rating and two have assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Reduce” and a consensus price target of $1.71.

View Our Latest Research Report on PACB

Pacific Biosciences of California Company Profile

(Get Free Report)

Pacific Biosciences of California, Inc (NASDAQ: PACB) is a life sciences technology company that develops and supplies DNA sequencing systems, consumables and related software. The company is best known for its single-molecule, real-time (SMRT) sequencing technology, which produces highly accurate long-read data used to analyze complex genomes, structural variation, genetic disease and other biological information.

PacBio’s product portfolio includes the Revio long-read sequencing system, the Sequel II and Sequel IIe platforms, sequencing consumables and the associated data-analysis software.